Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model

Documenti analoghi

• Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts
  di: Abuqayyas, Lubna, et al.
  Pubblicazione: (2012)
• STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
  di: Srivastava, Raghvendra M, et al.
  Pubblicazione: (2013)
• Inhibition of tumor growth by plant-derived mAb
  di: Ko, Kisung, et al.
  Pubblicazione: (2005)
• A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
  di: Lin, Po‐Lin, et al.
  Pubblicazione: (2017)
• PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
  di: Concha-Benavente, Fernando, et al.
  Pubblicazione: (2015)